Customize your JAMA Network experience by selecting one or more topics from the list below.
The true extent of the coronavirus disease 2019 (COVID-19) epidemic in the US is unknown. The 3.4 million confirmed cases reported (as of July 15, 2020) likely represent only a fraction of all the infections that have occurred in the US thus far. Limited laboratory capacity and restrictive testing guidelines early in the epidemic resulted in large numbers of undetected incident infections. Approximately 40% of all SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infections are thought to be asymptomatic,1 and active surveillance for infections without symptoms is limited even now, nearly 5 months after the first COVID-19 cases were reported in Seattle2 and Chicago.3 The true cumulative incidence of infection—a basic but critically important measurement—remains uncertain at a time when communities nationwide are struggling to navigate an ongoing, unprecedented public health emergency, and while apprehensions about the near-term and long-term trajectories of the epidemic loom large.
Brown TS, Walensky RP. Serosurveillance and the COVID-19 Epidemic in the US: Undetected, Uncertain, and Out of Control. JAMA. 2020;324(8):749–751. doi:10.1001/jama.2020.14017
Create a personal account or sign in to: